Medindia LOGIN REGISTER
Medindia
Advertisement

BioMed Realty Trust Promotes Kent Griffin to President

Monday, December 15, 2008 General News
Advertisement
SAN DIEGO, Dec. 15 BioMed Realty Trust, Inc.(NYSE: BMR), a real estate investment trust focused on providing real estateto the life science industry, today announced that Kent Griffin has beenpromoted to President and Chief Operating Officer. Mr. Griffin will overseethe day-to-day operational activities and execution of the Company's businessplan while continuing to serve as the Company's Chief Financial Officer.
Advertisement

Alan Gold, BioMed's Chief Executive Officer, remarked, "I am very pleasedthat the Board has chosen to recognize the contributions that Kent has made toBioMed, originating with him playing a key role in the Company's successfulinitial public offering in August 2004. As our Chief Financial Officer since2006, Kent has been a critical member of our leadership team, developing andexecuting key financial strategies, while also taking an increasingly integralrole in managing the growth of our organization and overseeing ouroperations."
Advertisement

Commenting on the promotion, Mr. Griffin said, "Alan and the BioMed teamhave built the premier real estate company for the life sciences industry witha portfolio of world-class life science research facilities. It is an honorand a privilege to be part of such a deep and talented team of real estateprofessionals committed to our mission -- creating value for our shareholdersand opportunities for our employees by being the leading provider of realestate to the life science industry."

About BioMed Realty Trust

BioMed Realty Trust, Inc. is a real estate investment trust (REIT) focusedon Providing Real Estate to the Life Science Industry(R). The company'stenants primarily include biotechnology and pharmaceutical companies,scientific research institutions, government agencies and other entitiesinvolved in the life science industry. BioMed Realty Trust owns or hasinterests in 69 properties, representing 112 buildings with approximately 10.4million rentable square feet, including approximately 1.4 million square feetof development in progress. The company also owns undeveloped land parcelsadjacent to existing properties that it estimates can support up to 1.4million rentable square feet. The company's properties are locatedpredominantly in the major U.S. life science markets of Boston, San Diego, SanFrancisco, Seattle, Maryland, Pennsylvania and New York/New Jersey, which havewell-established reputations as centers for scientific research. Additionalinformation is available at http://www.biomedrealty.com.

This press release contains forward-looking statements within the meaningof the Private Securities Litigation Reform Act of 1995 based on currentexpectations, forecasts and assumptions that involve risks and uncertaintiesthat could cause actual outcomes and results to differ materially. Theserisks and uncertainties include, without limitation: general risks affectingthe real estate industry (including, without limitation, the inability toenter into or renew leases, dependence on tenants' financial condition, andcompetition from other developers, owners and operators of real estate);adverse economic or real estate developments in the life science industry orthe company's target markets; risks associated with the availability and termsof financing and the use of debt to fund acquisitions and developments;failure to manage effectively the company's growth and expansion into newmarkets, or to complete or integrate acquisitions and developmentssuccessfully; risks and uncertainties affecting property development andconstruction; risks associated with downturns in the national and localeconomies, increases in interest rates, and volatility in the securitiesmarkets; potential liability for uninsured losses and environmentalcontamination; risks associated with the company's potential failure toqualify as a REIT under the Internal Revenue Code of 1986, as amended, andpossible adverse changes in tax and environmental laws; and risks associatedwith the company's dependence on key personnel whose continued service is notguaranteed. For a further list and description of such risks anduncertainties, see the reports filed by the company with the Securities andExchange Commission, including the company's most recent annual report on Form10-K and quarterly reports on Form 10-Q. The company disclaims any intentionor obligation to update or revise any forward-looking statements, whether as aresult of new information, future events or otherwise.

SOURCE BioMed Realty Trust, Inc.
Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close